Rare lephants
Screener

HeartSciences Inc.

HSCS ·Financial, Credit Services, United States
Analysis › Moat Score

Moat Score — HeartSciences Inc.

Total Moat Score 3 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 2 / 5 HeartSciences holds 8 U.S. utility patents, 1 design patent, and an exclusively licensed allowed patent, plus a Mount Sinai-licensed low-ejection-fraction algorithm, giving it real but early-stage IP that is not yet backed by an FDA-cleared product.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 As a 15-employee, pre-commercial company with no FDA clearance, HeartSciences has no cost advantage over its large, established ECG manufacturer competitors like GE and Philips.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 0 / 5 With no FDA-cleared product generating revenue, HeartSciences has no current pricing power; future pricing remains entirely speculative pending regulatory clearance and reimbursement determination.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 1 / 5 The device-agnostic MyoVista Insights Cloud Platform could, if adopted broadly, create a mild network benefit as more ECG machines connect to it, but this remains theoretical absent any current commercial deployment.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 0 / 5 With no commercialized product yet, HeartSciences has created no provider switching costs; any future lock-in would depend entirely on clinical adoption that has not yet begun.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 0 / 5 At 15 full-time employees and pre-revenue status, HeartSciences has no efficient-scale advantage whatsoever versus its large, well-resourced competitors in traditional ECG manufacturing or AI-healthcare diagnostics.